Framingham-based biopharmaceutical company Xenetic Biosciences (NASDAQ: XBIO) has seen its shares soar 32.37% over 21 trading sessions – an astounding increase at a time when NASDAQ shows only minor decline – making an unprecedented comeback after two consecutive periods of rapid expansion.
An Unexpected Turnaround
With shares soaring 58.3% since their 52-week high, Xenetic Biosciences’ recent share performance demonstrates an unexpected turnaround. Its surprising rise runs counter to recent trends and should be examined closely for insights.
Innovation is Key
Xenetic has become known for developing its proprietary CAR T platform XCART to design cell-based cancer therapies tailored specifically for individual patients. Furthermore, its PolyXen drug delivery platform has helped the company form partnerships with key industry players like Takeda Pharmaceutical Company Ltd and Serum Institute of India Limited.
A Look at the Financials
Financially, Xenetic Biosciences reported an EPS of 4.37 for its trailing twelve month earnings period ending March 2018, signaling increased profitability. Yet its return on equity stands at -39.06% indicating possible performance issues relative to shareholder’s equity. Such discrepancies highlight potential discrepancies within its financial health.
New Revenue Figures Ignite Hope
Investors might take comfort from Xenetic’s latest revenue figures. Year-on-year quarterly revenue growth has skyrocketed 55.7% and now stands at 1.92M for trailing twelve months – evidence that its innovative solutions have found favor with customers.
A Forward Look at Xenetic
As Xenetic continues its journey across the biomedical industry, investors should keep an eye on this stock. Although its performance has varied significantly over the years, its advancement in technologies and robust revenue growth indicate promise despite some previous performance discrepancies. Still, investors should proceed cautiously considering its negative return on equity ratio.
More news about Xenetic Biosciences (XBIO).
